Scynexis Advances SCY-770 into Phase 1 for ADPKD Treatment
Event summary
- Scynexis initiates Phase 1 study of SCY-770, a novel AMPK activator for ADPKD treatment.
- Study aims to characterize food-effect and pharmacokinetics of two dosing regimens.
- Topline data expected in Q3 2026, with Phase 2 proof-of-concept study planned for Q4 2026.
- SCY-770 has Orphan Drug Designation from the FDA for ADPKD treatment.
The big picture
Scynexis' advancement of SCY-770 into Phase 1 underscores the growing focus on AMPK activators for rare genetic disorders. The company aims to address significant unmet medical needs in ADPKD, a progressive kidney disorder with limited disease-modifying options. Success in this program could position Scynexis as a key player in the orphan drug space, particularly if SCY-770 demonstrates efficacy in slowing cyst growth and improving patient outcomes.
What we're watching
- Clinical Progress
- Whether SCY-770's Phase 1 data supports dose selection for the Phase 2 study.
- Regulatory Pathway
- The impact of Orphan Drug Designation on SCY-770's development timeline and commercial potential.
- Market Differentiation
- How SCY-770's mechanism compares to existing ADPKD treatments in slowing disease progression.
Related topics